Patents by Inventor Henrik Sune Andersen

Henrik Sune Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190203213
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Publication number: 20180221501
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Publication number: 20170305994
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20170239362
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 24, 2017
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Patent number: 9737612
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: August 22, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 9713644
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 9695226
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 4, 2017
    Assignee: Novo Nordisk HealthCare AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Publication number: 20140329750
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Henrik Sune Andersen, Nils Langeland Johansen, Jens Buchardt, Leif Noerskov-Lauritsen
  • Patent number: 8865868
    Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Carsten Behrens, Patrick William Garibay, Søren Østergaard, Henrik Sune Andersen, Nils Langeland Johansen, Bernd Peschke, Sonja Bak
  • Publication number: 20140294853
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Patent number: 8841249
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: September 23, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Leif Norskov-Lauritsen
  • Patent number: 8779109
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 15, 2014
    Assignee: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen
  • Patent number: 8765130
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 1, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20140107324
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt
  • Publication number: 20130336984
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 19, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20130330360
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 12, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Publication number: 20130143815
    Abstract: The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant.
    Type: Application
    Filed: July 15, 2011
    Publication date: June 6, 2013
    Applicant: NOVO NORDISK HEALTH CARE AG
    Inventors: Henrik Sune Andersen, Kjeld Madsen, Helle Demuth, Christine Bruun Schioedt, Leif Noerskov-Lauritsen, Peter Thygesen, Carsten Behrens, Mette Guldbrandt
  • Patent number: 8383668
    Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: February 26, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Soren Ebdrup, Henrik Sune Andersen
  • Patent number: 8383683
    Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydro-genase type 1 (11?HSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active gluco-corticoid is desirable.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: February 26, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Soren Ebdrup, Henrik Sune Andersen
  • Publication number: 20120309944
    Abstract: The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
    Type: Application
    Filed: January 24, 2011
    Publication date: December 6, 2012
    Applicant: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Nils Langeland Johansen, Henrik Sune Andersen, Leif Noerskov-Lauritsen, Jens Buchardt